Advertisement

Rolle von ausgewählten Mikronährstoffen beim Prostatakarzinom

  • R. MückeEmail author
  • O. Micke
  • J. Büntzel
Integrative Onkologie
  • 11 Downloads

Zusammenfassung

Hintergrund

Das Interesse sowohl von betreuenden Ärzten als auch Patienten mit einem Prostatakarzinom an der zusätzlichen Einnahme von Mikronährstoffen mit unterschiedlichen Intentionen nimmt zu. Dieses Update liefert deshalb eine Standortbestimmung zum zusätzlichen Einsatz von ausgewählten Mikronährstoffen beim Prostatakarzinom.

Methoden

Es wurde eine Literaturrecherche hinsichtlich des Einsatzes von ausgewählten Mikronährstoffen beim Prostatakarzinom, die bis 2017 in zitierfähigen Journalen erschienen sind, durchgeführt.

Ergebnisse

Daten zu Mikronährstoffen, die sowohl hinsichtlich der Prävention, der Lebensqualität während der onkologischen Therapie als auch der Prognose einen Nutzen für Patienten mit Prostatakarzinom bringen können und Erkenntnisse zu Mikronährstoffen, die für die Patienten keinen Benefit haben oder sogar schaden, werden präsentiert.

Schlussfolgerung

Nicht nur vorrangig onkologisch tätige Ärzte, sondern auch alle Ärzte, die Patienten mit einem Prostatakarzinom mitbetreuen, sollten Kenntnisse über die wichtigsten Mikronährstoffe haben, um diese an die Patienten weiterzugeben und sie auch gezielt zum Nutzen der Patienten einzusetzen.

Schlüsselwörter

Selen Vitamin D Vitamin C Vitamin A Folsäure 

The role of selected micronutrients in prostate cancer

Abstract

Background

There is great interest among prostate cancer patients for the additional use of micronutrients in order to improve the quality of life during oncological treatment. In contrast, many oncologists still reject the use of micronutrients for prevention and during tumor treatment. This update provides additional data to consider the use of selected micronutrients during treatment of prostate cancer.

Methods

A literature search was performed regarding articles on the use of selected micronutrients for prostate cancer patients that have been published up to 2017 in citable journals.

Results

This article presents selected data on micronutrients for prevention and in terms of quality of life and the prognosis for prostate cancer patients.

Conclusion

Physicians should be able to offer informed advice to prostate cancer patients and in those cases where the evidence warrants it, integrate the use of specific micronutrients into the treatment strategies.

Keywords

Selenium Vitamin D Vitamin C Vitamin A Folic acid 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

R. Mücke, O. Micke und J. Büntzel geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Wien TN, Pike E, Wisløff T, Staff A, Smeland S, Klemp M (2012) Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open 2(1):e653CrossRefGoogle Scholar
  2. 2.
    Nordström T, Van Blarigan EL, Ngo V, Roy R, Weinberg V, Song X, Simko J, Carroll PR, Chan JM, Paris PL (2016) Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer. Prostate 76(4):339–348CrossRefGoogle Scholar
  3. 3.
    Margalit DN, Kasperzyk JL, Martin NE, Sesso HD, Gaziano JM, Ma J, Stampfer MJ, Mucci LA (2012) Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians’ Health Study. Int J Radiat Oncol Biol Phys 83(1):28–32CrossRefGoogle Scholar
  4. 4.
    Ehrenpreis ED, Jani A, Levitsky J, Ahn J, Hong J (2005) A prospective, randomized, double-blind, placebo-controlled trial of Retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum 48(1):1–8CrossRefGoogle Scholar
  5. 5.
    Bai XY, Qu X, Jiang X, Xu Z, Yang Y, Su Q, Wang M, Wu H (2015) Association between dietary vitamin C intake and risk of prostate cancer: a meta-analysis involving 103,658 subjects. J Cancer 6:913–921CrossRefGoogle Scholar
  6. 6.
    Campbell GD Jr, Steinberg MH, Bower JD (1975) Letter: Ascorbic acid-induced hemolysis in G‑6-PD deficiency. Ann Intern Med 82:810CrossRefGoogle Scholar
  7. 7.
    Rees DC, Kelsey H, Richards JD (1993) Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306:841–842CrossRefGoogle Scholar
  8. 8.
    McCullough ML, Bostick RM, Mayo TL (2009) Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111–132CrossRefGoogle Scholar
  9. 9.
    Stanaland M, Jiroutek MR, Holland MA (2017) Study of the association between serum vitamin D levels and prostate cancer. Mil Med 182(5):e1769–e1774CrossRefGoogle Scholar
  10. 10.
    Albanes D, Mondul AM, Yu K et al (2011) Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 20(9):1850–1860CrossRefGoogle Scholar
  11. 11.
    Meyer HE, Robsahm TE, Bjorge T, Brustad M, Blomhoff R (2013) Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies. Am J Clin Nutr 97(1):147–154CrossRefGoogle Scholar
  12. 12.
    Gilbert R, Martin RM, Fraser WD, Lewis S, Donovan J, Hamdy F, Neal DE, Lane JA, Metcalfe C (2012) Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Control 23:575–588CrossRefGoogle Scholar
  13. 13.
    Wagner D, Trudel D, Van der Kwast T et al (2013) Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab 98(4):1498–1507CrossRefGoogle Scholar
  14. 14.
    Nyame YA, Murphy AB, Bowen DK et al (2016) Associations between serum vitamin D and adverse pathology in men undergoing radical prostatectomy. J Clin Oncol 34(12):1345–1349CrossRefGoogle Scholar
  15. 15.
    Mondul AM, Weinstein SJ, Moy KA, Mannisto S, Albanes D (2016) Circulating 25-Hydroxyvitamin D and prostate cancer survival. Cancer Epidemiol Biomarkers Prev 25(4):665–669CrossRefGoogle Scholar
  16. 16.
    Mücke R, Schomburg L, Büntzel J, Gröber U, Holzhauer P, Micke O (2010) Komplementärer Seleneinsatz in der Onkologie. Onkologe 16:181–186CrossRefGoogle Scholar
  17. 17.
    Bleys J, Navas-Acien A, Guallar E (2008) Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med 168:404–410CrossRefGoogle Scholar
  18. 18.
    Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. (2009) Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium and vitamin E cancer prevention trial (SELECT). JAMA 301:39–51CrossRefGoogle Scholar
  19. 19.
    Mücke R, Schomburg L, Büntzel J, Kisters K, Micke O, German Working Group Trace Elements and Electrolytes in Oncology (2010) Selenium or no selenium-that is the question in tumor patients: a new controversy. Integr Cancer Ther 9(2):136–141CrossRefGoogle Scholar
  20. 20.
    Geybels MS, Verhage BA, van Schooten FJ, Goldbohm RA, van den Brandt PA (2013) Advanced prostate cancer risk in relation to toenail selenium Levels. J Natl Cancer Inst 105(18):1394–1401CrossRefGoogle Scholar
  21. 21.
    Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Lippman SM, Klein EA (2014) Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. J Natl Cancer Inst 106(3):djt456CrossRefGoogle Scholar
  22. 22.
    Kim Y, Wei J, Citronberg J, Hartman T, Fedirko V, Goodman M (2015) Relation of vitamin E and selenium exposure to prostate cancer risk by smoking status: a review and meta-analysis. Anticancer Res 35(9):4983–4996PubMedGoogle Scholar
  23. 23.
    Chan JM, Darke AK, Penney KL et al (2016) Selenium- or vitamin E‑related gene variants, interaction with supplementation, and risk of high-grade prostate cancer in SELECT. Cancer Epidemiol Biomarkers Prev 25(7):1050–1058CrossRefGoogle Scholar
  24. 24.
    Xie W, Yang M, Chan J et al (2016) Association of genetic variations of selenoprotein genes, plasma selenium levels, and prostate cancer aggressiveness at diagnosis. Prostate 76(7):691–699CrossRefGoogle Scholar
  25. 25.
    Allen NE, Travis RC, Appleby PN et al (2016) Selenium and prostate cancer: analysis of individual participant data from fifteen prospective studies. J Natl Cancer Inst 108(11).  https://doi.org/10.1093/jnci/djw153 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cai X, Wang C, Yu W, Fan W, Wang S, Shen N, Wu P, Li X, Wang F (2016) Selenium exposure and cancer risk: an updated meta-analysis and meta-regression. Sci Rep 6:19213CrossRefGoogle Scholar
  27. 27.
    Outzen M, Tjonneland A, Larsen EH et al (2016) Selenium status and risk of prostate cancer in a Danish population. Br J Nutr 115(9):1669–1677CrossRefGoogle Scholar
  28. 28.
    Cui Z, Liu D, Liu C, Liu G (2017) Serum selenium levels and prostate cancer risk: a MOOSE-compliant meta-analysis. Medicine 96(5):e5944CrossRefGoogle Scholar
  29. 29.
    Kranse R, Dagnelie PC, van Kemenade MC et al (2005) Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer 113(5):835–840CrossRefGoogle Scholar
  30. 30.
    Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, Thompson PA, Clark LC, Ahmann FR (2010) Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. Cancer Prev Res (phila) 3(8):1035–1043CrossRefGoogle Scholar
  31. 31.
    Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, Giovannucci LE, Chan JM (2014) Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst 107(1):360CrossRefGoogle Scholar
  32. 32.
    Ansong E, Ying Q, Ekoue DN et al (2015) Evidence that selenium binding protein 1 is a tumor suppressor in prostate cancer. PLoS ONE 10(5):e127295CrossRefGoogle Scholar
  33. 33.
    Meyer F, Galan P, Douville P et al (2005) Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 116(2):182–186CrossRefGoogle Scholar
  34. 34.
    Leitzmann MF, Stampfer MJ, Wu K, Colditz GA, Willett WC, Giovannucci EL (2003) Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst 95(13):1004–1007CrossRefGoogle Scholar
  35. 35.
    Zhang Y, Coogan P, Palmer JR, Strom BL, Rosenberg L (2009) Vitamin and mineral use and risk of prostate cancer: the case-control surveillance study. Cancer Causes Control 20(5):691–698CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Standort Bad KreuznachStrahlentherapie RheinMainNaheBad KreuznachDeutschland
  2. 2.Klinik für Strahlentherapie und RadioonkologieRuhr-Universität BochumBochumDeutschland
  3. 3.Klinik für Strahlentherapie und RadioonkologieFranziskus-Hospital BielefeldBielefeldDeutschland
  4. 4.Klinik für HNO-HeilkundeSüdharzklinikum NordhausenNordhausenDeutschland

Personalised recommendations